New Clues To Cancer Growth Discovered

July 25, 1996

New Clues to Cancer Growth
Embargoed until: July 24, 1996, 5 p.m. EDT

Contact: Christine Westerman, (212) 639-3573

New Clues To Cancer Growth Discovered

NEW YORK, July 25, 1996 -- Scientists searching for molecular clues to cancer have produced a detailed picture showing how a key protein blocks a central promoter of cell growth involved in virtually all human cancers. The discovery sets the stage for developing drugs to mimic the protein, called p27, with the hope of halting the uncontrolled cell division that ultimately leads to the formation of tumors.

The three-dimensional image, produced in atom-by-atom detail using a combination of X-rays and crystals, is published in the July 25 issue of the scientific journal Nature by a team of researchers led by Nikola P. Pavletich, Ph.D., at Memorial Sloan-Kettering Cancer Center in New York City. The research is supported by the National Institutes of Health and the Howard Hughes Medical Institute.

Cell division in many tissues is regulated by the p27 protein, which binds to and inhibits enzymes called cyclin-dependent kinases (CDKs). The crystal structure reveals in intimate detail how p27 paralyzes CDKs, thereby arresting the cell cycle.

CDKs are so crucial to cell division that cells -- even those that are cancerous -- will not multiply without them. Thus, the role of CDKs in tumor growth is a main focus of cancer research, says Joan Massagué, Ph.D., Program Chairman for Cell Biology at Memorial Sloan-Kettering, and one of the paper's authors.

"Now that we understand exactly how p27 attaches to CDKs to halt the cell cycle, it may be possible to design or search for innovative cancer drugs that work in the same way," says Dr. Massagué, whose lab was the first to purify and clone p27 in 1994.

The researchers' high-tech picture also is likely to have broad implications for other inhibitory proteins in the p27 family, such as p21 and p57. "We expect these proteins, which are structurally very similar to p27, to bind to CDKs in almost the same way as p27," says Dr. Massagué. "This work is important because it establishes a general principle by which an entire family of inhibitors will block cell growth."

Under normal, healthy conditions, these inhibitors keep cell growth in check as part of a universal pathway that, when altered by genetic mutations, leads to cancer. "What is remarkable is that this pathway, at one step or another, is crippled in many cancers," Dr. Massagué says.

Researchers have known for several years that p27 exerts its inhibitory effect by binding to CDKs. CDKs are activated when they bind with cyclins. When it is time for a cell to divide, cyclins latch onto CDKs, and the resulting complex activates other enzymes to copy cells' DNA.

Now, by using a sophisticated technique called X-ray crystallography, Drs. Pavletich and Massagué and their colleagues have shown exactly how p27 attaches to the cyclin-CDK complex. The researchers bombarded crystals containing millions of copies of the p27-cyclin-CDK complex with intense X-rays directed from many different angles. They then used an electronic detector to gather information from X-rays that ricocheted off the crystals. A powerful computer analyzed the data, and the researchers used the resulting information to piece together the molecular structure.

The crystal structure reveals that p27 interacts with both members of the cyclin-kinase complex, in this case cyclin A and CDK2. Specifically, p27 inhibits cell division by inserting itself into a pocket in the cyclin-CDK complex that normally binds the energy molecule adenosine triphosphate (ATP). Without the phosphate from ATP, CDKs can't activate the enzymes that copy DNA.

In recent years, scientists at Memorial Sloan-Kettering have focused their efforts on elucidating the biological and chemical controls that govern the reproduction of individual cells. In 1994, in the journal Science, Dr. Pavletich reported using X-ray crystallography to identify the atomic structure of p53, a protein produced by a gene involved in triggering about half of all cancers. The p53 protein halts cell division by activating the p21 cell-cycle inhibitor protein.

Then in 1995, Drs. Pavletich and Massagué and their colleagues also used X-ray crystallography to identify one type of cyclin-CDK complex, which is one of the targets of the p21 and p27 inhibitors. This report was published in Nature.

The team now plans to use X-ray crystallography to reveal how another class of cell cycle inhibitors, among them p15 and p16, binds to cyclin-CDK complexes to halt cell division.

Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Throughout its long, distinguished history, the Center has played a leadership role in defining the standard of care for patients with cancer. In 1995, Memorial Sloan-Kettering was named the nation's best cancer center for the third consecutive year by U.S. News and World Report.
MSKCC press releases can be found on-line at:

Memorial Sloan Kettering Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to